Published in Mol Ther on April 21, 2009
A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther (2010) 1.54
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica (2010) 1.32
The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther (2011) 1.11
Hematopoietic stem cell engineering at a crossroads. Blood (2011) 1.10
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. Mol Ther (2010) 1.03
Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors. RNA (2012) 1.00
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood (2014) 0.97
A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res (2015) 0.89
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood (2016) 0.86
Identification and characterization of enhancer-blocking insulators to reduce retroviral vector genotoxicity. PLoS One (2013) 0.83
Modified gateway system for double shRNA expression and Cre/lox based gene expression. BMC Biotechnol (2011) 0.83
Prototypic chromatin insulator cHS4 protects retroviral transgene from silencing in Schistosoma mansoni. Transgenic Res (2011) 0.82
Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency. Stem Cells Cloning (2009) 0.82
Insulated Foamy Viral Vectors. Hum Gene Ther (2016) 0.79
Development of gene therapy for thalassemia. Cold Spring Harb Perspect Med (2012) 0.79
The GATA1-HS2 enhancer allows persistent and position-independent expression of a β-globin transgene. PLoS One (2011) 0.79
A chimeric HS4-SAR insulator (IS2) that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem cells. PLoS One (2014) 0.78
The human ankyrin 1 promoter insulator sustains gene expression in a β-globin lentiviral vector in hematopoietic stem cells. Mol Ther Methods Clin Dev (2015) 0.78
Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors. Genet Vaccines Ther (2011) 0.77
Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector. PLoS One (2014) 0.77
Cell cycle status of CD34(+) hemopoietic stem cells determines lentiviral integration in actively transcribed and development-related genes. Mol Ther (2014) 0.77
Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol (2016) 0.76
New insights into inhibition of human immunodeficiency virus type 1 replication through mutant tRNALys3. Retrovirology (2013) 0.76
Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells. Gene Ther (2017) 0.75
Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy. Biomedicines (2016) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Correct integration of retroviral DNA in vitro. Cell (1987) 10.73
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A (1992) 6.85
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
HIV-1 genome nuclear import is mediated by a central DNA flap. Cell (2000) 5.87
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proc Natl Acad Sci U S A (1990) 3.76
Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci U S A (1997) 3.57
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol (2001) 2.35
Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol (2004) 2.08
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood (2002) 1.89
Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther (2001) 1.88
Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci U S A (1989) 1.78
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Efficient packaging of readthrough RNA in ALV: implications for oncogene transduction. Science (1987) 1.65
Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A (2002) 1.61
The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol (2000) 1.60
Gene therapy: X-SCID transgene leukaemogenicity. Nature (2006) 1.57
Positional enhancer-blocking activity of the chicken beta-globin insulator in transiently transfected cells. Proc Natl Acad Sci U S A (1999) 1.56
Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther (2007) 1.42
The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Oncogene (1988) 1.41
Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther (2007) 1.40
Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood (2003) 1.40
Structural features in the HIV-1 repeat region facilitate strand transfer during reverse transcription. RNA (2001) 1.34
RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol (2002) 1.32
Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood (2002) 1.30
Self-inactivating retroviral vectors with improved RNA processing. Gene Ther (2004) 1.23
Integration complexes derived from HIV vectors for rapid assays in vitro. Nat Biotechnol (1999) 1.20
High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood (2001) 1.19
Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene (1996) 1.18
Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther (2007) 1.17
Replication of lengthened Moloney murine leukemia virus genomes is impaired at multiple stages. J Virol (2000) 1.13
In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription. Nucleic Acids Res (2000) 1.02
Alteration of nucleic acid structure and stability modulates the efficiency of minus-strand transfer mediated by the HIV-1 nucleocapsid protein. J Biol Chem (2004) 1.01
The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther (2007) 1.00
A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis (2007) 0.99
Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol (2002) 0.96
Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Ther (1995) 0.93
Cis-acting elements required for strong stop acceptor template selection during Moloney murine leukemia virus reverse transcription. J Mol Biol (1998) 0.93
Sequences in the 5' and 3' R elements of human immunodeficiency virus type 1 critical for efficient reverse transcription. J Virol (2000) 0.86
Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development. Gene Ther (1997) 0.79
Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys (2002) 5.16
IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys (2009) 4.47
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol (2009) 3.99
Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys (2003) 3.14
Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 2.35
Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys (2005) 2.33
Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys (2003) 2.29
Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys (2012) 2.11
Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood (2008) 2.09
Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.81
Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys (2002) 1.76
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys (2004) 1.70
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med (2014) 1.53
PON gene polymorphisms and ischaemic stroke: a systematic review and meta analysis. Int J Stroke (2012) 1.49
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther (2007) 1.40
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev (2012) 1.40
Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood (2008) 1.37
Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood (2003) 1.37
Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood (2003) 1.35
Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer (2008) 1.31
High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood (2010) 1.22
Dosimetric evaluation of automatic segmentation for adaptive IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.19
Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys (2008) 1.16
Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell (2008) 1.15
The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys (2002) 1.15
Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys (2007) 1.15
Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest (2003) 1.11
Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys (2008) 1.11
Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J (2011) 1.09
Investigation of the use of MOSFET for clinical IMRT dosimetric verification. Med Phys (2002) 1.09
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys (2007) 1.05
Unfaithful maintenance of methylation imprints due to loss of maternal nuclear Dnmt1 during somatic cell nuclear transfer. PLoS One (2011) 1.04
Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. Am J Med Genet A (2004) 1.03
Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. J Neurosurg Spine (2012) 1.03
Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood (2008) 1.02
Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A (2009) 1.00
Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.00
Regulation of IkappaB kinase (IKK) complex by IKKgamma-dependent phosphorylation of the T-loop and C terminus of IKKbeta. J Biol Chem (2006) 0.99
Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. Int J Radiat Oncol Biol Phys (2008) 0.99
Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood (2013) 0.98
Patient dose considerations for routine megavoltage cone-beam CT imaging. Med Phys (2007) 0.98
Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD). J Biol Chem (2010) 0.98
Can positron emission tomography (PET) or PET/Computed Tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys (2008) 0.98
Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med (2006) 0.98
Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp Hematol (2004) 0.97
Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther (2007) 0.95
Method to account for dose fractionation in analysis of IMRT plans: modified equivalent uniform dose. Int J Radiat Oncol Biol Phys (2005) 0.95
Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys (2012) 0.95
Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther (2004) 0.94
Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys (2003) 0.93
Dose calculation using megavoltage cone-beam CT. Int J Radiat Oncol Biol Phys (2007) 0.93
A new smoothing procedure to reduce delivery segments for static MLC-based IMRT planning. Med Phys (2004) 0.93
A population-based atlas and clinical target volume for the head-and-neck lymph nodes. Int J Radiat Oncol Biol Phys (2004) 0.93
Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. Int J Radiat Oncol Biol Phys (2011) 0.93
Biomarkers for early detection of sickle nephropathy. Am J Hematol (2011) 0.92
Molecular characterization of the human NANOG protein. Stem Cells (2009) 0.90
A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 0.90
Comparison between hybrid direct aperture optimized intensity-modulated radiotherapy and forward planning intensity-modulated radiotherapy for whole breast irradiation. Int J Radiat Oncol Biol Phys (2010) 0.90
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest (2015) 0.90
Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One (2012) 0.87
Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapy. J Appl Clin Med Phys (2013) 0.87
Aberrant expression and methylation status of putatively imprinted genes in placenta of cloned piglets. Cell Reprogram (2010) 0.87
Assessing feasibility of real-time ultrasound monitoring in stereotactic body radiotherapy of liver tumors. Technol Cancer Res Treat (2013) 0.86
Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.86
Sensitivity and specificity of immunocytochemical staining of mycobacterial antigens in the cytoplasm of cerebrospinal fluid macrophages for diagnosing tuberculous meningitis. J Clin Microbiol (2011) 0.86
RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitors. J Exp Med (2013) 0.85
Tbx3 and Nr5α2 play important roles in pig pluripotent stem cells. Stem Cell Rev (2013) 0.85
Detection of treatment setup errors between two CT scans for patients with head and neck cancer. Med Phys (2007) 0.84
Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci (2010) 0.84
Germinal vesicle chromatin configurations of bovine oocytes. Microsc Res Tech (2006) 0.83
Flattening filter-free accelerators: a report from the AAPM Therapy Emerging Technology Assessment Work Group. J Appl Clin Med Phys (2015) 0.83
Image-guided radiotherapy using megavoltage cone-beam computed tomography for treatment of paraspinous tumors in the presence of orthopedic hardware. Int J Radiat Oncol Biol Phys (2006) 0.82
An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys (2007) 0.82
Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program (2010) 0.82
Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias. Expert Rev Mol Med (2006) 0.82
Effects of the intensity levels and beam map resolutions on static IMRT plans. Med Phys (2004) 0.81
Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg Med Chem Lett (2005) 0.81
A feasibility study of using conventional jaws to deliver IMRT plans in the treatment of prostate cancer. Phys Med Biol (2007) 0.81
Alignment focus of daily image guidance for concurrent treatment of prostate and pelvic lymph nodes. Int J Radiat Oncol Biol Phys (2013) 0.81
Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat (2012) 0.80
Can posterior dynamic stabilization reduce the risk of adjacent segment deterioration? Turk Neurosurg (2013) 0.80
Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. ScientificWorldJournal (2010) 0.80
Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.80
Effect of MLC leaf width on treatment adaptation and accuracy for concurrent irradiation of prostate and pelvic lymph nodes. Med Phys (2013) 0.79
Comparison of intensity-modulated radiosurgery with gamma knife radiosurgery for challenging skull base lesions. Int J Radiat Oncol Biol Phys (2003) 0.79